

REGULATORY UPDATE ON ANIMAL HEALTH PRODUCT

Melbourne, 13 January 2011: Acrux (ASX: ACR) today provided an update on the status of the marketing application for the first animal health product utilising Acrux's delivery technology, which was submitted by Acrux's licensee Elanco (a division of Eli Lilly and Company), to the US FDA's Center for Veterinary Medicine (CVM).

CVM has determined in its review that one technical section of the marketing application is incomplete. Elanco is currently in dialogue with CVM to agree the requirements for the completion of this section. These additional requirements may result in a delay to the decision on approval of the application, although the extent of any such delay has not been determined, and is pending Elanco's further discussions with CVM. The financial impact on Acrux of the delay is not material.

Contact:

Richard Treagus, CEO: +61 417 520 509; richard.treagus@acrux.com.au

About Acrux - www.acrux.com.au

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.
- Fast-drying, invisible sprays or liquids provide a delivery platform with low or no skin irritation, superior cosmetic acceptability and simple, accurate and flexible dosing. The technology platform is covered by broad and well-differentiated, issued patents.
- Acrux has two products approved for marketing in the USA, one product in registration in the USA, one product in registration in Europe and further products at earlier stages of development.
- Acrux received two 2010 Governor of Victoria Export Awards, including the Victorian Export Award for Innovation Excellence.